Clearside Biomedical Announces Positive 6-Month Results
- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders -...
Source: globenewswire.com
Page 3 - Extension Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Extension Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Extension Study Today - Breaking & Trending Today
Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA ORS® (edaravone) for the Treatment of ALS
/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the U.S. Food and Drug Administration (FDA) has approved RADICAVA ORS®...
Source: prnewswire.com
GSK Singapore announces availability of Shingrix in Singapore for shingles prevention
SINGAPORE, Jan. 10, 2022 /PRNewswire/ -- GlaxoSmithKline (GSK) Singapore announced that a new vaccine to help protect against shingles, Shingrix, is now available in Singapore. Shingrix is a non-live, recombinant subunit adjuvanted vaccine, given intramuscularly in two doses, for the prevention of shingles (herpes zoster). The vaccine was initially approved for adults aged 50 years and over, with the...
Source: asiaone.com
Investegate |Sanofi Announcements | Sanofi: New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021
Investegate announcements from Sanofi, New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021
Source: investegate.co.uk
Sanofi: New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 One-year results from Phase 2b extension study of brain-penetrant tolebrutinib
Source: finanznachrichten.de